We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00036309
Recruitment Status : Completed
First Posted : May 9, 2002
Last Update Posted : July 19, 2006
Information provided by:
Eli Lilly and Company

Brief Summary:
The purpose of this study is to determine if duloxetine is effective when compared to placebo in preventing recurrence of major depressive disorder in patients who have responded to open-label duloxetine treatment.

Condition or disease Intervention/treatment Phase
Depressive Disorder Drug: Duloxetine Hydrochloride Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder
Study Start Date : May 2002
Study Completion Date : July 2003

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed the informed consent
  • Meet criteria for major depressive disorder without psychotic features.
  • Have a level of understanding sufficient to provide informed consent and to communicate with the investigator and site personnel.
  • Have had at least one other major depressive episode prior to the one being experienced at study entry.
  • You are reliable and agree to keep all appointments for clinic visits, tests and procedures required by the protocol.

Exclusion Criteria:

  • You have had treatment with a drug within the last 30 days that has not received regulatory approval at the time of study entry.
  • Any women who are pregnant or breast feeding.
  • If you have any serious medical illnesses other than major depressive disorder.
  • If you have previously participated in a clinical trial for duloxetine.
  • Any previous or current diagnosis of bipolar, schizophrenia, or other psychotic disorders.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00036309

Layout table for location information
United States, North Carolina
For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)
Durham, North Carolina, United States
Sponsors and Collaborators
Eli Lilly and Company
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00036309    
Other Study ID Numbers: 4445
First Posted: May 9, 2002    Key Record Dates
Last Update Posted: July 19, 2006
Last Verified: July 2006
Keywords provided by Eli Lilly and Company:
Major Depressive Disorder
Diagnostic and Statistical Manual of Mental Disorders Fourth Edition-defined major depressive disorder without psychotic features
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Depressive Disorder, Major
Pathologic Processes
Mood Disorders
Mental Disorders
Behavioral Symptoms
Duloxetine Hydrochloride
Serotonin and Noradrenaline Reuptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Antidepressive Agents
Psychotropic Drugs
Dopamine Agents